These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30192805)

  • 1. Knowledge, stigma, health seeking behaviour and its determinants among patients with post kalaazar dermal leishmaniasis, Bihar, India.
    Garapati P; Pal B; Siddiqui NA; Bimal S; Das P; Murti K; Pandey K
    PLoS One; 2018; 13(9):e0203407. PubMed ID: 30192805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
    Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
    Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S
    J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
    Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
    PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Arsenic Exposure and Risk of Post Kala-azar Dermal Leishmaniasis Development in India: A Retrospective Cohort Study.
    Das S; Mandal R; Rabidas VN; Verma N; Pandey K; Ghosh AK; Kesari S; Kumar A; Purkait B; Lal CS; Das P
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005060. PubMed ID: 27776123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India.
    Das VN; Ranjan A; Pandey K; Singh D; Verma N; Das S; Lal CS; Sinha NK; Verma RB; Siddiqui NA; Das P
    Am J Trop Med Hyg; 2012 Jun; 86(6):959-61. PubMed ID: 22665600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
    Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P
    J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
    Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A
    Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Study on Health Seeking Behaviors of Patients of Post-Kala-Azar Dermal Leishmaniasis.
    Basher A; Nath P; Nabi SG; Selim S; Rahman MF; Sutradhar SR; Faiz A; Bhuiyan MR; Ahmed BN; Rahman R
    Biomed Res Int; 2015; 2015():314543. PubMed ID: 26788500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
    Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
    PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal Study of Transmission in Households with Visceral Leishmaniasis, Asymptomatic Infections and PKDL in Highly Endemic Villages in Bihar, India.
    Das VN; Pandey RN; Siddiqui NA; Chapman LA; Kumar V; Pandey K; Matlashewski G; Das P
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005196. PubMed ID: 27974858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
    Zijlstra EE; Alves F; Rijal S; Arana B; Alvar J
    PLoS Negl Trop Dis; 2017 Nov; 11(11):e0005877. PubMed ID: 29145397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced case of PKDL due to delayed treatment: A rare case report.
    Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.
    Goyal V; Das VNR; Singh SN; Singh RS; Pandey K; Verma N; Hightower A; Rijal S; Das P; Alvar J; Bern C; Alves F
    PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008429. PubMed ID: 32687498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
    Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
    J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved kala-azar case management through implementation of health facility-based sentinel sites surveillance system in Bihar, India.
    Das VNR; Siddiqui NA; Bhunia GS; Pandey K; Sinha SK; Ansari MZ; Topno RK; Lal CS; Ranjan A; Singh VP; Das P
    PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009598. PubMed ID: 34428232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of post kala-azar dermal leishmaniasis (PKDL) and treatment seeking behavior of PKDL patients in Nepal.
    Joshi AB; Banjara MR; Das ML; Ghale P; Pant KR; Parajuli N; Pyakurel UR; Dahal GR; Das CL; Kroeger A; Aseffa A
    PLoS Negl Trop Dis; 2023 Feb; 17(2):e0011138. PubMed ID: 36758102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
    Moulik S; Chaudhuri SJ; Sardar B; Ghosh M; Saha B; Das NK; Chatterjee M
    Clin Infect Dis; 2018 Jan; 66(3):404-410. PubMed ID: 29020350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
    Mukhopadhyay D; Mukherjee S; Ghosh S; Roy S; Saha B; Das NK; Chatterjee M
    Int J Dermatol; 2016 May; 55(5):e250-5. PubMed ID: 26536363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.